8400 The Health Network
Gili Hart is an accomplished biotechnology executive with extensive experience in leadership roles within the industry. Currently serving as Chief Executive Officer at SpliSense, Gili Hart leads a clinical stage company focused on innovative RNA-based treatments for pulmonary diseases. Gili Hart holds board member positions at Enlivex Therapeutics and Quicklizard, and has been involved with 8400 The Health Network since June 2019. Previous roles include CEO at Mitoconix Bio. Ltd, General Manager at OPKO Biologics, and Vice President of Preclinical and Clinical Pharmacology at OPKO Biologics (formerly Prolor Biotech LTD). Gili Hart's academic background includes a PhD and Master's in Immunology from the Weizmann Institute of Science, along with a B.Sc in Biotechnology Engineering from the Technion Institute of Technology, and a research fellowship at Yale School of Medicine.
This person is not in any teams